Bank of America reissued their underperform rating on shares of BioXcel Therapeutics (NASDAQ:BTAI – Free Report) in a research report released on Tuesday morning,Benzinga reports. They currently have a $0.25 price objective on the stock, down from their prior price objective of $7.00.
Several other equities analysts have also issued reports on the stock. HC Wainwright lowered their target price on shares of BioXcel Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a report on Monday, October 21st. Canaccord Genuity Group lowered their target price on shares of BioXcel Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a report on Monday.
Check Out Our Latest Analysis on BTAI
BioXcel Therapeutics Stock Performance
Hedge Funds Weigh In On BioXcel Therapeutics
A number of hedge funds have recently added to or reduced their stakes in BTAI. Point72 Asia Singapore Pte. Ltd. purchased a new position in BioXcel Therapeutics in the 2nd quarter worth approximately $39,000. XTX Topco Ltd raised its holdings in BioXcel Therapeutics by 49.0% in the 2nd quarter. XTX Topco Ltd now owns 46,503 shares of the company’s stock worth $60,000 after acquiring an additional 15,291 shares during the last quarter. Finally, Armistice Capital LLC raised its holdings in BioXcel Therapeutics by 705.2% in the 2nd quarter. Armistice Capital LLC now owns 2,987,000 shares of the company’s stock worth $3,823,000 after acquiring an additional 2,616,027 shares during the last quarter. 30.68% of the stock is currently owned by hedge funds and other institutional investors.
About BioXcel Therapeutics
BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.
Featured Stories
- Five stocks we like better than BioXcel Therapeutics
- Transportation Stocks Investing
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Compound Interest and Why It Matters When Investing
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.